Phase I trial of recombinant fusion protein PIXY321 for mobilization of peripheral-blood cells

Mobilization of peripheral-blood cells (PBC) with cytokines alone results in rapid hematopoietic recovery and avoids the potential morbidity associated with mobilization by chemotherapy. PIXY321, a fusion protein that consists of granulocyte-macrophage colony-stimulating factor (GM-CSF) and interleu...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of clinical oncology 1996-09, Vol.14 (9), p.2521-2526
Hauptverfasser:	BISHOP, M. R, JACKSON, J. D, O'KANE-MURPHY, B, SCHMIT-POKORNY, K, VOSE, J. M, BIERMAN, P. J, WARKENTIN, P. I, ARMITAGE, J. O, GARRISON, L, KESSINGER, A
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy Antigens, CD34 - analysis Biological and medical sciences Blood Component Removal Bone marrow, stem cells transplantation. Graft versus host reaction Colony-Forming Units Assay Granulocyte-Macrophage Colony-Stimulating Factor - administration & dosage Granulocyte-Macrophage Colony-Stimulating Factor - adverse effects Hematopoietic Stem Cell Transplantation Hematopoietic Stem Cells - drug effects Humans Interleukin-3 - administration & dosage Interleukin-3 - adverse effects Lymphoma - blood Lymphoma - therapy Medical sciences Middle Aged Recombinant Fusion Proteins - administration & dosage Recombinant Fusion Proteins - adverse effects Transfusions. Complications. Transfusion reactions. Cell and gene therapy
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!